Viyash Scientific Reports Strong Q1 FY27 Results, Driven by Growth and Integration Efforts
Hyderabad: Viyash Scientific Limited (formerly SeQuent Scientific Limited) announced its unaudited financial results for the quarter ended June 30, 2026. The company, which operates across Formulations, APIs, and CDMO Services for both Human and Animal health, reported robust growth in Q1 FY27, reflecting successful integration efforts and improved operational leverage.The company's standalone performance showed significant gains. Revenues reached ₹ 9,464 Million, marking a 19.5% increase. EBITDA stood at ₹ 2,047 Million, which saw a substantial rise of 59.2%. Furthermore, Profit After Tax (PAT) was reported at ₹ 793 Million, representing an increase of 114.9%. The company's Net Debt / EBITDA* ratio improved to 0.1 x.
Consolidated Performance Review
The consolidated financial results demonstrate a steady upward trajectory for the company:| Metric | Q1 FY27 (₹ Million) | Q1 FY26 (₹ Million) | Growth Percentage |
|---|---|---|---|
| Revenues | 9,464 | 7,916 | 19.5% |
| EBITDA* | 2,047 | 1,286 | 59.2% |
| EBITDA% | 21.6% | 16.2% | N/A |
| PAT | 793 | 369 | 114.9% |
EBITDA refers to EBITDA excluding ESOP costs.
Management Highlights Focus on Strategic Growth
Dr Hari Babu Bodepudi, Managing Director and Group CEO, commented that the Q1 FY27 performance underscores the success of the company's integration efforts and the strength of its combined entity. He stated that the results were supported by robust execution, improving operating leverage, and a clearly defined growth strategy.A key strategic move noted was the acquisition of Bio For Life in Italy. Dr Bodepudi emphasized that this acquisition is a significant step towards advancing their focus on the companion animal segment, granting Viyash market access and providing a platform to launch its product portfolio across key European markets. Moving forward, the company plans to maintain disciplined execution, operational efficiency, and strategic investments aligned with its long-term strategy for sustainable growth.
The management will conduct an Earnings call on August 12, 2026, at 3:30 PM IST, during which they plan to discuss the company's performance and address participant questions.
VIYASH Stock Price Movement
Viyash Scientific Limited's shares slipped by 3.60% to settle at ₹261.45 today after trading in a highly volatile session. The stock saw significant activity during post-market hours, with over 6.7 million shares changing hands.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.